Apr 4AlgernonAlgernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical StudyVANCOUVER, British Columbia, April 04, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN)...